R & D
User Name :
Password :
Administrator Login   
Research & Development
Research and Development (R&D) plays a leading role in our company. 3B BlackBio Biotech has developed new technologies, services and products thanks to a sustained investment in research and development, that we continue to leverage as we innovate for the future. We are focused on our customers, putting our scientific and problem-solving capabilities to work in order to guarantee their success.
3B Blackbio Biotech India is licensee of the gelification technology covered by an international Biotools B&M Labs. patent.
Our Management of Research and Development constantly reviews and revises its task loading to be effective in its future search for new discipline and avenue of research with innovation and practical applications.
Our experience of more than a decade in production of molecular Biology reagents & other related products makes us competent to provide integral solutions in the areas of Molecular Diagnostics, Pharmacogenomics and Life Sciences.
At Biotools and 2B BlackBio (our Promoters in Spain), we thrive on working with our customers to answer their needs. Our goal is to keep on doing just that –making dreams real.
We continually invest in research and development to provide our customers with the resources and answers they need. This has enabled our scientific community to maintain a keen focus on things that really matter - technologies that improve our lives and change our world.
We have developed many proprietary technologies, as a result of our R & D efforts as :
  • Specialized Non-chromatographic procedure for DNA polymerase and other thermostable enzymes purification.
  • Stabilization method for Biomolecules and Complex reaction mixtures through gelification,which relieves the worry of -20˚C freezers for storing PCR reagents.
  • Eight recombinant thermostable enzymes: Taq DNA polymerase, Tth DNA polymerase, Pfu DNA polymerase, Tth ligase, SSB protein, chaperonins, Tth DNA polymerase recombinant in Thermus thermophilus, and GrO HIV reverse-transcriptase.
  • Cloning and expression systems of the developed recombinant thermostable enzymes in Escherichia coli and in Thermus thermophilus.
  • Innovative pyrosequencing process that helps us to bring sequencing into routine diagnostics and personalized medicine.
Our international R & D Team’s target is to lead the research and development of new tools in the field of personalized medicine, medical diagnostics and pharmacogenomics.
Our partner 2B BlackBio develops and markets new solutions for personalized medicine based on genetics, genomics and proteomics (more than five international patents). We are also progressing vigorously through our research to make Personalized Medicine a reality, translating genomic and proteomic advances to the Company, an become an international benchmark in the personalized medicine market.
We have developed BlackLight® Sepsis Kit which identifies bacteria to the level of species, and in some cases to the level of strain, by generating high quality sequence data covering three regions of the 16S ribosomal gene. This sequence data is then compared to bacterial ribosomal databases provided with the kit, and the most likely candidate organisms are displayed through High-through put sequencing technology, with the advantafe if being faster than any traditional method for bacterial identification, as diagnosis can be completed in less than 5 hours, optimizing the appropriate antifungal treatment to improve prognosis and treatment of infection, thus avoiding resistances and improving survival.
Blackbio within its line of Microbiology has launched BlackLight® Fungal ID Kit which allows the detection and identification of fungi and yeast in a biological sample with high sensibility and specificity. Handling is minimal with these kits, minimizing possible contamination, and it is faster than any traditional method for fungal identification, as diagnosis can be completed in less than 5 hours, optimizing the appropriate antifungal treatment to improve prognosis and treatment of infection, thus avoiding resistances and improving survival.
Our R & D covering the full range of topics in research, development, design and innovation to explore the possible solutions that help pharmaceutical companies & Physicians to improve health & betterment of life of patients . The pipe-line projects in our R & D are :
  • Development of advanced molecular approach for the Rapid and Eminent Detection of Multidrug resistance stains of Mycobacterium tuberculosis (considering 5 drugs(1st line) or 9drugs(1st & 2nd line))
  • Kit for β-Thalassemia Genotyping
  • Pharmacogenetics Assay for Diabetes Type-2
  • Prognostic Assay for Diabetes Type-2
Our R & D initiatives in Personalized Medicine and Companion Diagnostics (CDx) helps in the quest for better & safer drugs, providing pharmaceutical companies with essential tools that are turning to diagnostic tests to match the right drug to right patient with right dosage.
Our research focuses also on the identification of biomarkers that indicate which patient might benefit or not from a particular drug. Analyzing the genetic information, this helps in ensuring most cost-effective treatment with minimum side-effects.
Our team moves with the following strategies in R & D :
  • Application of new, proprietary, state-of-art technologies for the detection of genomic and proteomic biomarkers
  • International scope of technology development.
  • Focus in Pharmacogenomics, Metabolic Disorders, Oncology, Wellness, Cardiovascular, Allergy, and Microbiology
For additional information please contact us at info@3bblackbio.com
Home About 3B Diagnostics R & D Career Sitemap Contact Us
Powered By :Business Buddies
All Right Reserved-3B BlackBio Biotech India Limited